TAIPEI — OBIGEN (ticker symbol: 7876) announced plans to list its shares on the Taiwan Emerging Stock Market on November 24, 2025, with a reference price set at NT$50 per share.
The company has established an integrated business model that spans proprietary bacterial strain research, GMP manufacturing of both active pharmaceutical ingredient (API) and finished drug product, and advanced process development. OBIGEN aims to leverage its patented platform technologies and R&D capabilities to expand its presence in both aesthetic and therapeutic botulinum toxin markets worldwide.
Core Growth Drivers and Technological Focus
OBIGEN's long-term growth is driven by three key areas:
Differentiated Product: The company’s proprietary 760-kilodalton (kDa) complex molecular structure and patented formulation are designed to improve onset speed, extend therapeutic duration, and enhance purity and safety. Furthermore, its animal-free and alcohol-free production process has secured Halal certification, allowing access to Muslim-majority markets.
Global Market Expansion: The new botulinum toxin clinical trials benefit from a streamlined monitoring period, strong participant engagement, and rapid enrollment. OBIGEN plans to commence the participant enrollments of the Phase III clinical trials in Taiwan by the end of 2025 and submit an Investigational New Drug (IND) application for a Phase II trial to the U.S. FDA in early 2026. The studies are expected to produce internationally comparable clinical data to support future regulatory filings and potential licensing deals.
Blue Ocean Market for Long-Acting Botulinum Toxin: Global demand for botulinum toxin products is rising significantly due to broader aesthetic and therapeutic applications. OBIGEN's pipeline is positioned to capture significant value within the industry’s fastest-growing, higher-value segments, creating strong potential for out-licensing opportunities, strategic partnerships, and future M&A activities.
“The listing represents a key milestone that will fuel the next stage of OBIGEN’s growth. It provides additional momentum to advance our research, clinical development, and commercialization efforts. As global demand continues to grow for long-acting, high-purity botulinum toxin products, OBIGEN will build on its R&D strengths and expand its market presence to support sustainable, long-term growth,” said Dr. Heidi Wang, Chairperson of OBIGEN.
Distinct Product Advantages Driving Global Opportunities
Success in entering the global botulinum toxin market hinges on delivering a customer experience that surpasses existing products. OBIGEN’s OBI-858 leverages dual advantages—rapid onset (visible results as early as Day 3) and long duration (over half of participants maintaining improvements for more than six months)—while maintaining a well-balanced safety profile. These attributes address unmet market demands for both quick onset and long duration, positioning OBI-858 to break free from the industry’s standardized low-price competition.
At launch, the product will target major markets that prioritize high quality, fast onset, durable results, and overall cost-effectiveness. This strategy is expected to attract a broader base of aesthetic consumers and accelerate market adoption.
OBIGEN plans to initiate Phase III participant enrollment for glabellar line indication in Taiwan this December, with trial completion anticipated in the second half of 2026 and a market launch in Taiwan by 2028. The company also intends to submit an IND application to the U.S. FDA early next year to begin Phase II clinical trials, aiming for a global launch by 2030.
Therapeutic Expansion and Halal Market Access
Beyond its aesthetic applications, OBI-858 is being evaluated for multiple therapeutic uses to expand the platform’s application scope. A Phase II clinical trial for cervical dystonia is planned in the United States, with potential future indications in chronic migraine, post-stroke spasticity, overactive bladder, hyperhidrosis, and blepharospasm.
These therapeutic areas span neurology, dermatology, ophthalmology, urology, and rehabilitation medicine—markets that generally feature higher entry barriers, more stable pricing, and longer product life cycles. This diversification strategy is expected to strengthen OBIGEN’s competitive position and broaden its revenue streams.
The strategic attainment of Halal certification provides a significant commercial advantage. Based on its high-purity, animal-origin-free manufacturing process, OBI-858 is reported to be one of only two botulinum toxin brands globally with this qualification. This is the key to facilitating access to the rapidly growing Islamic markets in the Middle East, North Africa, and Southeast Asia.
Strengthening Patents and Manufacturing Foundations: Differentiated Advantages with Capital Appeal
In terms of intellectual property, OBI-858 features a globally pioneering 760 kDa molecular structure. Patents have been granted in 12 countries, including Taiwan, the U.S., Japan, Korea, Southeast Asia, the Middle East, and Australia/New Zealand, with an additional six countries pending, establishing a worldwide technological moat.
Production of high-toxicity protein drugs requires strict biosafety measures and process development. OBIGEN has overcome significant technical barriers, creating competitive advantages by investing in self-owned API and injectable facilities that comply with PIC/S GMP standards, ensuring that both manufacturing processes and product quality meet international standards.
From an industry perspective, innovative, long-acting botulinum toxin products with patent protection have become high-growth targets of interest for the global capital market. As clinical development progresses and international expansion deepens, OBIGEN’s product portfolio demonstrates considerable market potential and licensing value, positioning the company to maintain strategic control in future international licensing and partnership opportunities, thereby enhancing its capital attractiveness and competitive industry advantage.
Looking ahead, fueled by global population aging and growing demand for quality of life, botulinum toxin has become a transformative force in both aesthetic and medical applications. Strong global market demand continues to expand its use in non-invasive cosmetic treatments and clinical therapies, revealing a broad growth horizon. OBIGEN is actively extending its botulinum toxin platform across new indications and delivery technologies, developing novel formulations and usage methods, and accelerating international market penetration through strategic collaborations, licensing, and overseas distribution. The company is committed to providing innovative solutions for the global aesthetic and medical markets, supporting people in their pursuit of health and beauty.
About OBIGEN
OBIGEN PHARMA, Inc. is Taiwan’s only and global first 760 kDa botulinum toxin developer and manufacturer, with patent-protected strains and formulations, and advanced production technologies. OBIGEN is committed to providing the high quality and differentiated toxin solutions across aesthetics and therapeutics to help people pursue health and beauty in harmony.
Contact Information
Sheila Chuang, Deputy Spokesperson
Phone: +886 2786 1217 EXT.160
Email: sheilachuang@obigenpharma.com